CL2019001993A1 - Inhibidores selectivos de jak1. - Google Patents

Inhibidores selectivos de jak1.

Info

Publication number
CL2019001993A1
CL2019001993A1 CL2019001993A CL2019001993A CL2019001993A1 CL 2019001993 A1 CL2019001993 A1 CL 2019001993A1 CL 2019001993 A CL2019001993 A CL 2019001993A CL 2019001993 A CL2019001993 A CL 2019001993A CL 2019001993 A1 CL2019001993 A1 CL 2019001993A1
Authority
CL
Chile
Prior art keywords
jak1
selective inhibitors
document
formula
disclosed
Prior art date
Application number
CL2019001993A
Other languages
English (en)
Inventor
Matti Juhani Lepistö
Karl Magnus Nilsson
Annika Birgitta Margareta Åstrand
Anna Ingrid Kristina Berggren
Johan R Johansson
Sameer Pralhad Kawatkar
Qibin Su
Jason Grant Kettle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2019001993A1 publication Critical patent/CL2019001993A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE DESVELAN EN EL PRESENTE DOCUMENTO COMPUESTOS DE FÓRMULA (I), Y SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, EN LA QUE R1-R8 TIENEN CUALQUIERA DE LOS SIGNIFICADOS DEFINIDOS EN EL PRESENTE DOCUMENTO. ADEMÁS, SE DESVELAN COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN COMPUESTOS DE FÓRMULA (I) Y MÉTODOS DE USO DE LOS MISMOS.
CL2019001993A 2017-01-17 2019-07-15 Inhibidores selectivos de jak1. CL2019001993A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762447057P 2017-01-17 2017-01-17

Publications (1)

Publication Number Publication Date
CL2019001993A1 true CL2019001993A1 (es) 2019-12-27

Family

ID=61024756

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001993A CL2019001993A1 (es) 2017-01-17 2019-07-15 Inhibidores selectivos de jak1.

Country Status (36)

Country Link
US (3) US10961228B2 (es)
EP (2) EP3571192B1 (es)
JP (3) JP6986086B2 (es)
KR (2) KR102585048B1 (es)
CN (2) CN110461830B (es)
AR (1) AR110753A1 (es)
AU (1) AU2018209667B2 (es)
CA (1) CA3049175A1 (es)
CL (1) CL2019001993A1 (es)
CO (1) CO2019007888A2 (es)
CR (1) CR20190332A (es)
DK (1) DK3571192T3 (es)
DO (1) DOP2019000184A (es)
EA (1) EA037067B1 (es)
EC (1) ECSP19051352A (es)
ES (1) ES2938648T3 (es)
FI (1) FI3571192T3 (es)
HR (1) HRP20230069T1 (es)
HU (1) HUE061064T2 (es)
IL (1) IL267851B (es)
JO (1) JOP20190174B1 (es)
LT (1) LT3571192T (es)
MA (1) MA47301B1 (es)
MX (2) MX2019008435A (es)
NI (1) NI201900077A (es)
PE (1) PE20191108A1 (es)
PH (1) PH12019501639A1 (es)
PL (1) PL3571192T3 (es)
PT (1) PT3571192T (es)
RS (1) RS63981B1 (es)
SG (1) SG11201906222WA (es)
SI (1) SI3571192T1 (es)
TW (1) TWI753089B (es)
UA (1) UA124246C2 (es)
WO (1) WO2018134213A1 (es)
ZA (1) ZA201906875B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2938648T3 (es) * 2017-01-17 2023-04-13 Astrazeneca Ab Inhibidores selectivos de JAK1
HUE056472T2 (hu) 2017-01-26 2022-02-28 Hanmi Pharm Ind Co Ltd Pirimidin vegyület és annak gyógyszerészeti felhasználása
MX2021000611A (es) * 2018-07-18 2021-04-13 Astrazeneca Ab Una sal de xinafoato de un compuesto inhibidor de jak.
AU2019344878B2 (en) * 2018-09-21 2022-08-11 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Aromatic heterocyclic compound with kinase inhibitory activity
KR20220003537A (ko) 2019-04-19 2022-01-10 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 Jak1 선택적 키나제 억제제
WO2021207302A1 (en) * 2020-04-09 2021-10-14 Disarm Therapeutics, Inc. Indazole derivatives as inhibitors of sarm1
US20240025884A1 (en) * 2022-07-05 2024-01-25 Dong-A St Co., Ltd. Compounds as gcn2 inhibitors, pharmaceutical compositions and uses thereof
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法
WO2024150110A1 (en) * 2023-01-11 2024-07-18 Pfizer Inc. Compositions and methods for the treatment and/or prevention of type 1 diabetes
CN115974845B (zh) * 2023-01-19 2024-09-20 奥锐特药业股份有限公司 奥希替尼中间体的制备方法
US20240307353A1 (en) * 2023-03-16 2024-09-19 Incyte Corporation Jak1 pathway inhibitors for the treatment of asthma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005295788A1 (en) * 2004-10-13 2006-04-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
CN101421250A (zh) * 2006-01-30 2009-04-29 埃克塞里艾克西斯公司 作为jak-2调节剂的4-芳基-2-氨基-嘧啶或4-芳基-2-氨基烷基-嘧啶及包含它们的药物组合物
WO2009046416A1 (en) * 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
AU2011224484A1 (en) 2010-03-10 2012-09-27 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
TW201217387A (en) * 2010-09-15 2012-05-01 Hoffmann La Roche Azabenzothiazole compounds, compositions and methods of use
EP3060234A1 (en) 2013-10-24 2016-08-31 AbbVie Inc. Jak1 selective inhibitor and uses thereof
CA2995430C (en) * 2015-09-25 2023-07-11 Dizal (Jiangsu) Pharmaceutical Co., Limited Compounds and methods for inhibiting jak
ES2938648T3 (es) * 2017-01-17 2023-04-13 Astrazeneca Ab Inhibidores selectivos de JAK1

Also Published As

Publication number Publication date
AR110753A1 (es) 2019-05-02
RS63981B1 (sr) 2023-03-31
US20240208947A1 (en) 2024-06-27
HUE061064T2 (hu) 2023-05-28
ES2938648T3 (es) 2023-04-13
TWI753089B (zh) 2022-01-21
FI3571192T3 (fi) 2023-03-06
PT3571192T (pt) 2023-02-21
IL267851A (en) 2019-09-26
JP2024010041A (ja) 2024-01-23
MX2022002976A (es) 2022-04-06
CA3049175A1 (en) 2018-07-26
SG11201906222WA (en) 2019-08-27
PE20191108A1 (es) 2019-08-26
PL3571192T3 (pl) 2023-03-20
CN115925693A (zh) 2023-04-07
EA201991700A1 (ru) 2020-01-28
KR102659213B1 (ko) 2024-04-18
BR112019014526A2 (pt) 2020-02-27
MA47301B1 (fr) 2023-02-28
EP3571192A1 (en) 2019-11-27
KR20230141938A (ko) 2023-10-10
CO2019007888A2 (es) 2019-07-31
KR20190104215A (ko) 2019-09-06
EP3571192B1 (en) 2022-11-30
AU2018209667A1 (en) 2019-08-22
ZA201906875B (en) 2021-05-26
JP7394820B2 (ja) 2023-12-08
IL267851B (en) 2021-08-31
JP2020506171A (ja) 2020-02-27
HRP20230069T1 (hr) 2023-03-17
UA124246C2 (uk) 2021-08-11
JOP20190174A1 (ar) 2019-07-14
US20210188821A1 (en) 2021-06-24
DK3571192T3 (da) 2023-02-06
EA037067B1 (ru) 2021-02-02
CN110461830A (zh) 2019-11-15
JOP20190174B1 (ar) 2023-09-17
NI201900077A (es) 2020-03-18
MX2019008435A (es) 2019-09-09
SI3571192T1 (sl) 2023-03-31
TW201838984A (zh) 2018-11-01
LT3571192T (lt) 2023-02-27
DOP2019000184A (es) 2019-08-15
WO2018134213A1 (en) 2018-07-26
KR102585048B1 (ko) 2023-10-05
JP6986086B2 (ja) 2021-12-22
EP4219470A1 (en) 2023-08-02
CR20190332A (es) 2019-09-13
US20190367490A1 (en) 2019-12-05
US11897869B2 (en) 2024-02-13
PH12019501639A1 (en) 2020-07-06
MA47301A (fr) 2019-11-27
ECSP19051352A (es) 2019-07-31
JP2022043059A (ja) 2022-03-15
AU2018209667B2 (en) 2020-05-07
CN110461830B (zh) 2022-11-01
US10961228B2 (en) 2021-03-30

Similar Documents

Publication Publication Date Title
CL2019001993A1 (es) Inhibidores selectivos de jak1.
CO2020007244A2 (es) Inhibidores de kras g12c
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CL2019002609A1 (es) Compuestos heterocíclicos útiles como inhibidores dobles atx/ca.
UY37205A (es) Inhibidores de bromodominios
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
CR20150436A (es) Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo
CO2017011151A2 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CR20160419A (es) Nuevos compuestos biciclicos
CO7121325A2 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
CR20150524A (es) Compuestos de heteroarilo y sus usos
CL2017000820A1 (es) Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
DOP2015000170A (es) Compuestos químicos
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
CO2020004977A2 (es) Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
GT201300225A (es) Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia
UY36958A (es) Compuestos para administración intracelular
UY36464A (es) Compuestos de quinazolina